Provided by Tiger Fintech (Singapore) Pte. Ltd.

CLIMB BIO INC

1.27
-0.0300-2.31%
Post-market: 1.270.00000.00%19:58 EDT
Volume:241.65K
Turnover:303.00K
Market Cap:85.69M
PE:-0.83
High:1.37
Open:1.30
Low:1.23
Close:1.30
Loading ...

Company Profile

Company Name:
CLIMB BIO INC
Exchange:
NASDAQ
Establishment Date:
2018
Employees:
18
Office Location:
20 William Street,Suite 145,Wellesley Hills,Massachusetts,United States
Zip Code:
02481
Fax:
- -
Introduction:
Climb Bio, Inc., a biotechnology company, focuses on developing therapies for autoimmune-driven inflammatory diseases. It develops budoprutug, an anti-CD19 monoclonal antibody for various autoimmune diseases, including systemic lupus erythematosus and lupus nephritis, immune thrombocytopenia, and membranous nephropathy. The company was formerly known as Eliem Therapeutics, Inc. and changed its name to Climb Bio, Inc. in October 2024. Climb Bio, Inc. was incorporated in 2018 and is headquartered in Wilmington, Delaware.

Directors

Name
Position
Andrew Levin
Chairman of the Board
Robert Azelby
Chief Executive Officer and Director
Adam Rosenberg
Director
Judith Dunn
Director
Leone Patterson
Director
Liam Ratcliffe
Director
Simon Tate
Director

Shareholders

Name
Position
Robert Azelby
Chief Executive Officer and Director
Erin M. Lavelle
Executive Vice President, Chief Operating Officer and Chief Financial Officer
James B. Bucher
Executive Vice President and General Counsel
Valerie Morisset
Executive Vice President, Research and Development and Chief Scientific Officer